Short-term and long-term in vivo exposure to an ephedra- and caffeine-containing metabolic nutrition system does not induce cardiotoxicity in B6C3F1 mice

Archives of Toxicology

Volumn 79, Issue 6, 2005, Pages 330-340

  Ray, Sidhartha ^a,c   Phadke, Santosh ^a   Patel, Chintan ^a   Hackman, Robert M ^b   Stohs, Sidney ^c  

^a LONG ISLAND UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CREIGHTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CAFFEINE; CREATINE KINASE; EPHEDRA EXTRACT; GINKGO BILOBA EXTRACT; GREEN TEA EXTRACT; GUARANA EXTRACT; HERBACEOUS AGENT; LACTATE DEHYDROGENASE; MINERAL; OCIMUM BASILICUM EXTRACT; OMEGA 3 FATTY ACID; PLANT EXTRACT; UNCLASSIFIED DRUG; VITAMIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; BLOOD SAMPLING; BODY WEIGHT; CARDIOTOXICITY; CITRUS FRUIT; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENERGY; FEMALE; FOOD INTAKE; HEART; HISTOPATHOLOGY; MOUSE; NONHUMAN; NUTRITION; NUTRITIONAL SUPPORT; PRIORITY JOURNAL; THERMOGENESIS;

ANIMALS; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BODY WEIGHT; CAFFEINE; CREATINE KINASE; DIETARY SUPPLEMENTS; EPHEDRA; FEMALE; HEART; L-LACTATE DEHYDROGENASE; MICE; MICE, INBRED STRAINS; MYOCARDIUM; NUTRITION PHYSIOLOGY; TIME FACTORS;

ANIMALIA; CITRUS; EPHEDRA; OCIMUM; PAULLINIA CUPANA;

EID: 20544433207     PISSN: 03405761     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00204-005-0672-6     Document Type: Article

References (26)

1. Astrup A, Toubro S, Cannon S, Hein P, Breum L, Madsen J (1990) Caffeine: a double-blind, placebo-controlled study of its thermogenic, metabolic, and cardiovascular effects in healthy volunteers. Am J Clin Nutr 51(5):759-767
2. Astrup A, Toubro S, Cannon S, Hein P, Madsen J (1991) Thermogenic synergism between ephedrine and caffeine in healthy volunteers: a double-blind, placebo-controlled study. Metabolism 40:323-329
3. Astrup A, Buemann B, Christensen NJ (1992) The effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women. Metabolism 41:686-688
4. Bent S, Tiedt TN, Odden MC, Shlipak MG (2003) The relative safety of ephedra compared with other herbal products. Ann Intern Med 138:468-471
5. Boozer CN, Nasser JA, Heymsfield SB, Wang V, Chen G, Solomon JL (2001) An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial. Int J Obes Relat Metab Disord 25(3):316-324
6. Boozer CN, Daly PA, Homel P (2002) Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. Int J Obes Relat Metab Disord 26:593-604
7. Chen KK (1926a) The acute toxicity of ephedrine. J Pharmacol Exp Ther 27:61-76
8. Chen KK (1926b) The effect of repeated administration of ephedrine. J Pharmacol Exp Ther 27:77-86
9. Chen KK, Schmidt CF (1924) The action of ephedrine, the active principle of the Chinese drug Ma Huang. J Pharmacol Exp Ther 24:339-357
10. CRN (2002) The CANTOX report on ephedra. Council for Responsible Nutrition, Washington DC (see http://www.crnusa.org/cantoxoverview.html)
11. Dulloo AG (2002) Herbal simulation of ephedrine and caffeine in treatment of obesity. Int J Obes Relat Metab Disord 26:590-592
12. Dulloo AG, Miller DS (1987) Reversal of obesity in the genetically obese fa/fa Zucker rat with an ephedrine/methylxanthines thermogenic mixture. J Nutr 117:383-389
13. Daly PA, Krieger DR, Dulloo AG, Young JB, Landsberg L (1993) Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity. Int J Obes Relat Metab Disord 17(Suppl 1):S73-S78
14. FDA (2004) Final ruling on ephedra sales. US Food and Drug Administration, Rockville, MD (see http://www.fda.gov/ OHRMS/DOCKETS/98fr/1995n- 0304-nfr0001.pdf)
15. Haller CA, Benowitz NL (2000) Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 343:1833-1838
16. Haller CA, Jacob P III, Benowitz NL (2002) Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. Clin Pharmacol Ther 71:421-432
17. Molnar D, Torok K, Erhardt E, Jeges S (2000) Safety and efficacy of treatment with an ephedrine/caffeine mixture. The first double-blind placebo-controlled pilot study in adolescents. Int J Obes Relat Metab Disord 24:1573-1578
18. Morgenstern LB, Viscoli CM, Kernan WN (2003) Use of Ephedracontaining products and risk for hemorrhagic stroke. Neurology 60:132-135
19. Niemann RA, Gay ML (2003) Determination of ephedrine alkaloids and synephrine in dietary supplements by column-switching cation exchange high-performance liquid chromatography with scanning-wavelength ultraviolet and fluorescence detection. J Agr Food Chem 51:5630-5638
20. RAND (2003) Evidence Report/Technology Assessment Number 76: Ephedra and ephedrine for weight loss and athletic performance enhancement: Clinical efficacy and side effects. RAND Health Study, RAND Corporation, Santa Monica, CA (see http://www.fda.gov/bbs/topics/NEWS/ephedra/summary.html)
21. Ray SD (1999) Cell death and apoptosis. In: Ballantyne B, Marrs T, Turner P (eds) General and applied toxicology, vol I. Stockton/McMillan Publications, AZ, Ch 9, pp 176-200
22. Ray SD, Mumaw VR, Fariss MW (1996) Protection of acetaminophen-induced hepatocellular apoptosis and necrosis by cholesteryl hemisuccinate pretreatment. J Pharmacol Exp Ther 279(3):1470-1483
23. Shekelle PG, Hardy ML, Morton SC (2003) Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 289:1537-1545
24. Toubro S, Astrup AV, Breum L, Quaade F (1993) Safety and efficacy of long-term treatment with ephedrine, caffeine and an ephedrine/caffeine mixture. Int J Obes Relat Metab Disord 17(Suppl 1):S69-S72
25. White LM, Gardner SF, Gurley BJ, Marx MA, Wang PL, Estes M (1997) Pharmacokinetics and cardiovascular effects of ma-huang (Ephedra sinica) in normotensive adults. J Clin Pharmacol 37:116-122
26. Zahn KA, Li RL, Purssell RA (1999) Cardiovascular toxicity after ingestion of "herbal ecstacy". J Emerg Med 17:289-291